Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
Recruiting now · Phase 1/Phase 2
Conditions studied: Relapsed / Refractory Osteosarcoma
In brief
This is a multi-center, non-randomized, open-label, dosimetry and dose-escalation, cohort-expansion study of LNTH-2403 administered to subjects with relapsed / refractory (R/R) osteosarcoma. This study consists of 2 phases: (1) a dosimetry and dose escalation phase; and (2) a cohort expansion phase.
Key facts
- Study ID
- NCT07357519
- Run by
- Lantheus Medical Imaging
- People needed
- 55
- Starts
- 2026-02-03
- Expected to finish
- 2032-05-01
- Last updated by the study team
- 2026-05-01
Who can join
Age: 12 and older. Sex: any. Healthy volunteers: not accepted.
You may not qualify if…
- Participants meeting any of the following criteria will be excluded from the study
- Known allergies, hypersensitivity, or intolerance to LNTH-2403 and/or its excipients
- Prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, may affect the participant's safety, compliance with the study, or otherwise impair the assessment of study results
- Concurrent treatment with any other anti-neoplastic agents, including localized radiation therapy
- Known active infection
- Participation in an interventional study of another investigational agent
- Prior therapies or diagnostics
- Active prior or concurrent malignancy: immunoglobulin),
- Known active liver disease from any cause, Hepatitis A Virus
- Known to be human immunodeficiency virus (HIV) positive
- Clinically relevant cardiovascular disease
- Receipt of live vaccine within the 30 days prior to the first dose o
- A female participant who is pregnant or breastfeeding
- Major surgical procedure within 28 days of the first dose of LNTH-2403.
- Participant is unwilling or unable to comply with the scheduled visits, drug administration plan, laboratory tests, or other study procedures and study restrictions
Where it is running
- UCLA — Los Angeles, California, United States (enrolling)
- Dana Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.